183 related articles for article (PubMed ID: 27430430)
1. Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
Nwangwu CA; Weiher H; Schmidt-Wolf IGH
Hematol Oncol; 2017 Dec; 35(4):719-725. PubMed ID: 27430430
[TBL] [Abstract][Full Text] [Related]
2. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
[TBL] [Abstract][Full Text] [Related]
3. Enhancing cytokine-induced killer cell therapy of multiple myeloma.
Liu C; Suksanpaisan L; Chen YW; Russell SJ; Peng KW
Exp Hematol; 2013 Jun; 41(6):508-17. PubMed ID: 23403007
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
6. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
[TBL] [Abstract][Full Text] [Related]
7. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
8. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.
Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R
J Clin Immunol; 2010 Sep; 30(5):766-74. PubMed ID: 20549316
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
10. CIK Cells and HDAC Inhibitors in Multiple Myeloma.
Stephan D; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468247
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
[TBL] [Abstract][Full Text] [Related]
12. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.
Fionda C; Malgarini G; Soriani A; Zingoni A; Cecere F; Iannitto ML; Ricciardi MR; Federico V; Petrucci MT; Santoni A; Cippitelli M
J Immunol; 2013 Jun; 190(12):6662-72. PubMed ID: 23686482
[TBL] [Abstract][Full Text] [Related]
14. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation.
Andresen L; Skovbakke SL; Persson G; Hagemann-Jensen M; Hansen KA; Jensen H; Skov S
J Immunol; 2012 Feb; 188(4):1847-55. PubMed ID: 22227571
[TBL] [Abstract][Full Text] [Related]
15. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer.
Huang B; Sikorski R; Sampath P; Thorne SH
J Immunother; 2011 Apr; 34(3):289-96. PubMed ID: 21389869
[TBL] [Abstract][Full Text] [Related]
16. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway.
Pu J; Sharma A; Liu T; Hou J; Schmidt-Wolf IG
Clin Transl Immunology; 2024; 13(3):e1500. PubMed ID: 38529413
[TBL] [Abstract][Full Text] [Related]
17. High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells.
Garofano F; Schmidt-Wolf IGH
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471216
[TBL] [Abstract][Full Text] [Related]
18. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
Morisaki T; Hirano T; Koya N; Kiyota A; Tanaka H; Umebayashi M; Onishi H; Katano M
Anticancer Res; 2014 Aug; 34(8):4529-38. PubMed ID: 25075096
[TBL] [Abstract][Full Text] [Related]
19. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
[TBL] [Abstract][Full Text] [Related]
20. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma.
Bullok KF; Sippel C; Schmidt-Wolf IG
Hematol Oncol; 2016 Dec; 34(4):208-216. PubMed ID: 25784599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
